Who are BICTEGRAVIR SODIUM's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Biktarvy, TENOFOVIR ALAFENAMIDE FUMARATE, Vemlidy, Emtriva, Ziagen, Videx.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bictegravir-sodium.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

BICTEGRAVIR SODIUM — Competitive Intelligence Brief

BICTEGRAVIR SODIUM (BICTEGRAVIR SODIUM) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC].

marketed Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] Small molecule Live · refreshed every 30 min

Target snapshot

BICTEGRAVIR SODIUM (BICTEGRAVIR SODIUM).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Approval / PDUFA
BICTEGRAVIR SODIUM TARGET	BICTEGRAVIR SODIUM		marketed	Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]	2018-01-01
Biktarvy	BICTEGRAVIR	Gilead Sciences	marketed	Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]	2018-01-01
TENOFOVIR ALAFENAMIDE FUMARATE	TENOFOVIR ALAFENAMIDE FUMARATE		marketed	Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]	2015-01-01
Vemlidy	TENOFOVIR ALAFENAMIDE	Gilead Sciences	marketed	Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]	2015-01-01
Emtriva	EMTRICITABINE	Gilead Sciences	marketed	Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]	2003-01-01
Ziagen	ABACAVIR	GSK	marketed	Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor	1998-01-01
Videx	DIDANOSINE	Bristol-Myers Squibb	marketed	Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor	1991-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2032-08-15 — Biktarvy · 9296769 · US
2032-08-15 — Biktarvy · 8754065 · US
2033-02-15 — Biktarvy · 8754065*PED · US
2033-02-15 — Biktarvy · 9296769*PED · US
2033-12-19 — Biktarvy · 9216996 · US
2033-12-19 — Biktarvy · 9732092 · US
2035-06-19 — Biktarvy · 9708342 · US
2035-06-19 — Biktarvy · 10385067 · US
2036-11-08 — Biktarvy · 10548846 · US

Sponsor landscape (Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class)

Gilead Sciences · 3 drugs in this class
· 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BICTEGRAVIR SODIUM — Competitive Intelligence Brief. https://druglandscape.com/ci/bictegravir-sodium. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab